Jinkai Biotech announced that shareholder Qilu Investment plans to reduce its holdings by no more than 3.612 million shares, accounting for 3% of the company's total share capital. Among them, holdings were reduced by no more than 1.204 million shares through centralized bidding, accounting for 1% of the company's total share capital; holdings were reduced by no more than 2.408 million shares through bulk transactions, accounting for 2% of the company's total share capital. Shareholder Qingsong Investment plans to reduce its holdings by no more than 1.24 million shares through centralized bidding, accounting for 1% of the company's total share capital. The holdings reduction period is three months after 15 trading days from the date of the announcement.

Jinkai Biotech announced that shareholder Qilu Investment plans to reduce its holdings by no more than 3.612 million shares, accounting for 3% of the company's total share capital. Among them, holdings were reduced by no more than 1.204 million shares through centralized bidding, accounting for 1% of the company's total share capital; holdings were reduced by no more than 2.408 million shares through bulk transactions, accounting for 2% of the company's total share capital. Shareholder Qingsong Investment plans to reduce its holdings by no more than 1.24 million shares through centralized bidding, accounting for 1% of the company's total share capital. The holdings reduction period is three months after 15 trading days from the date of the announcement.